PeptideCompareSemaglutide vs Retatrutide
How do Semaglutide and Retatrutide compare for GLP-1 & Weight research? Side-by-side evidence, molecular profile, EU legal status and COA-verified supplier prices — never dosing advice.
At a glance
Semaglutide
Retatrutide
Which fits which research target?
Both Semaglutide and Retatrutide sit within GLP-1 & Weight research but are studied for different primary signals. Semaglutide exists as an EMA-authorised medicine (the licensed product is not the research vial sold by vendors), while Retatrutide is not an approved medicine — compare the evidence, not marketing claims.
What the research shows
Semaglutide
Retatrutide
Compare prices across EU suppliers
Compare Semaglutide across EU suppliers
4 EU vendors · COA · from €64.95
Compare Retatrutide across EU suppliers
21 EU vendors · COA · from €44.49
Frequently asked questions
Is Semaglutide or Retatrutide better? ▾
Only Semaglutide exists as an EMA-authorised medicine, and “better” depends on the research target. Semaglutide is most associated with Weight reduction, while Retatrutide is studied for Weight reduction. Compare the evidence tiers and COA-verified EU pricing above rather than assuming one is superior. This is not a usage recommendation.
Why compare Semaglutide and Retatrutide? ▾
Both are studied within GLP-1 & Weight research through different mechanisms, so researchers often weigh them against each other. This page sets their evidence, molecular profile, EU legal status and supplier pricing side by side.
Which is cheaper in the EU, Semaglutide or Retatrutide? ▾
Prices vary by supplier, vial size and COA status. Semaglutide is listed from €64.95 across 4 COA-verified EU vendors; Retatrutide from €44.49 across 21. Open the price pages above to compare current listings — nobody pays us for placement.